Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2026-04-14 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
Earnings Release Classification · 92% confidence The document is an ad hoc announcement by Kuros Biosciences pursuant to SIX listing rules, summarizing first quarter 2026 key financial metrics (sales growth, EBITDA, adjusted EBITDA, cash) and operational highlights. It serves as the initial public earnings release for Q1, providing high‐level performance figures rather than full interim financial statements. This aligns with the definition of an Earnings Release (ER). Q1 2026
2026-04-14 English
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
Report Publication Announcement Classification · 95% confidence The document is an 'Ad-hoc announcement' regarding financial results for the full year 2025. It provides key financial highlights, management commentary, and operational updates. Crucially, it explicitly states 'The Kuros Biosciences Annual Report 2025 can be downloaded via the following link' and provides a URL, indicating that this document is an announcement of the report rather than the full 10-K/Annual Report itself. Therefore, it falls under the Report Publication Announcement (RPA) category.
2026-03-10 English
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' detailing financial performance for the first nine months of 2025, including revenue, EBITDA, and operational highlights. While it contains financial data, it is structured as a press release (media release) rather than a formal statutory interim report. According to the 'Menu vs Meal' rule, this is an initial announcement of results rather than the full report itself. Given the focus on quarterly/periodical financial highlights and the announcement of guidance, it fits the definition of an Earnings Release (ER). 9M 2025
2025-10-16 English
Kuros statement on media inquiry concerning former Board member
Legal Proceedings Report Classification · 100% confidence The document is an ad-hoc announcement issued pursuant to SIX listing rules regarding a media inquiry about a former board member. It addresses a specific corporate event/investigation rather than a recurring financial report, management change announcement (as the person is already a 'former' member), or legal proceeding report. Given it is a regulatory-mandated disclosure of a sensitive corporate matter, it falls under the general regulatory filing category.
2025-09-18 English
Kuros Biosciences announces changes in the Board of Directors
Board/Management Information Classification · 100% confidence The document is an ad-hoc announcement regarding changes in the Board of Directors of Kuros Biosciences, specifically the resignation of a board member and new appointments to the Audit and Risk Committee and the Compensation and Nomination Committee. This aligns perfectly with the definition for Board/Management Information (MANG).
2025-09-04 English
Kuros Biosciences Reports First Half of 2025 Results
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc announcement' regarding Kuros Biosciences' financial results for the first half of 2025. It provides a summary of financial highlights, operational updates, and key figures. Crucially, the document explicitly states at the end that the full 'Half Year Report 2025' can be downloaded via an external link, and it provides links for a webcast and presentation. Following the 'Menu vs Meal' rule, because this document is an announcement summarizing results and directing the reader to the full report, it is classified as a Report Publication Announcement (RPA). H1 2025
2025-08-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.